Publications

Vyome’s research team actively contributes to the scientific community, publishing on immune signaling, antimicrobial resistance, and novel therapeutic mechanisms.

Abstract CT091: Interim results from a phase 2 trial testing the safety and efficacy of VT-1953 topical gel in patients with malodorous malignant fungating wound

Arshit Narang, Prashant Prakash Lad, Shiladitya Sengupta

Topically Applied VT-1908 Reduces Uveitis-associated Inflammation (Abstract ID: 190259)

Jyoti Chauhan, Shiladitya Sengupta

Treatment recalcitrant cases of tinea corporis/cruris caused by T. mentagrophytes - interdigitale complex with mutations in ERG11 ERG 3, ERG4, MDR1 MFS genes & SQLE and their potential implications

Bhattacharyya A, Sadhasivam S, Sinha M, Gupta S, Saini S, Singh H, Khurana A, Sachdeva S, Sardana K, Ghosh S. Int J Dermatol.

A potent antibiotic-loaded bone-cement implant against staphylococcal bone infections

Ghosh S, Sinha M, Samanta R, Sadhasivam S, Bhattacharyya A, Nandy A, Saini S, Tandon N, Singh H, Gupta S, Chauhan A, Aavula KK, Varghese SS, Shi P, Ghosh S, Garg MK, Saha T, Padhye A, Ghosh S, Jang HL, Sengupta S.

Checkerboard Analysis To Evaluate Synergistic Combinations of Existing Antifungal Drugs and Propylene Glycol Monocaprylate in Isolates from Recalcitrant Tinea Corporis and Cruris Patients Harboring Squalene Epoxidase Gene Mutation

Sardana K, Gupta A, Sadhasivam S, Gautam RK, Khurana A, Saini S, Gupta S, Ghosh S. Antimicrob Agents Chemother.

Mechanistic Insight Into the Antifungal Effects of a Fatty Acid Derivative Against Drug-Resistant Fungal Infections

Bhattacharyya A, Sinha M, Singh H, Patel RS, Ghosh S, Sardana K, Ghosh S, Sengupta S. Front Microbiol.

Checkerboard Analysis To Evaluate Synergistic Combinations of Existing Antifungal Drugs and Propylene Glycol Monocaprylate in Isolates from Recalcitrant Tinea Corporis and Cruris Patients Harboring Squalene Epoxidase Gene Mutation

Sardana K, Gupta A, Sadhasivam S, Gautam RK, Khurana A, Saini S, Gupta S, Ghosh S. Antimicrob Agents Chemother.

Mechanistic Insight Into the Antifungal Effects of a Fatty Acid Derivative Against Drug-Resistant Fungal Infections

Bhattacharyya A, Sinha M, Singh H, Patel RS, Ghosh S, Sardana K, Ghosh S, Sengupta S. Front Microbiol.

Efficacy and Safety of VB-1953 Topical Gel in Non-Responder Acne Patients with Clindamycin-Resistant Cutibacterium acnes

Batra R, Sadhasivam S, Saini S, Gupta S, Bisen RKS, Sinha M, Ghosh S, Jain S. Drugs R D.

Newly Developed Anti-Dandruff Regimen, VB-3222, Delivers Enhanced Sensorial and Effective Therapeutic Benefits Against Moderate Adherent Dandruff

Sadhasivam S, Garkhal K, Singh H, Yadav V, Chawrai S, Ramnane M, Jain S, Sardana K, Ghosh S. Clin Cosmet Investig Dermatol.haryya A, Sadhasivam S, Sinha M, Gupta S, Saini S, Singh H, Khurana A, Sachdeva S, Sardana K, Ghosh S. Int J Dermatol.

A Rationally Designed Multifunctional Antibiotic for the Treatment of Drug-Resistant Acne

Ghosh S, Sinha M, Bhattacharyya A, Sadhasivam S, Megha J, Reddy S, Saini S, Singh H, Kumar D, Kaur SP, Mishra M, Usharani D, Ghosh S, Sengupta S. J Invest Dermatol.

Antibiotic-resistant acne: getting under the skin

Sinha M, Sadhasivam S, Bhattacharyya A, Jain S, Ghosh S, Arndt KA, Dover JS, Sengupta S. Semin Cutan Med Surg.

Heterogeneity and antibiotic resistance in Propionibacterium acnes isolates and its therapeutic implications: blurring the lines between commensal and pathogenic phylotypes

Sadhasivam S, Sinha M, Saini S, Kaur SP, Gupta T, Sengupta S, Ghosh S, Sardana K. Dermatol Ther.

Evaluation of therapeutic potential of VB-001, a leave-on formulation, for the treatment of moderate adherent dandruff

Bhattacharyya A, Jain N, Prasad S, Jain S, Yadav V, Ghosh S, Sengupta S. BMC Dermatol.

Heterogeneity and antibiotic resistance in Propionibacterium acnes isolates and its therapeutic implications: blurring the lines between commensal and pathogenic phylotypes

Sadhasivam S, Sinha M, Saini S, Kaur SP, Gupta T, Sengupta S, Ghosh S, Sardana K. Dermatol Ther.

Antibiotic-resistant acne: getting under the skin

Sinha M, Sadhasivam S, Bhattacharyya A, Jain S, Ghosh S, Arndt KA, Dover JS, Sengupta S. Semin Cutan Med Surg.

A Cambridge, MA, based global healthcare platform synergizing biotech, medical devices, and AI.

Vyome Holdings, Inc.
Nasdaq: HIND

PRINCIPAL OFFICE

Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138

PHONE

+1 973-832-8147

SUBSIDIARIES

⁠Vyome Therapeutics, Inc.

OFFICE

Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138

Vyome Therapeutics Limited, Subsidiary of Vyome Therapeutics, Inc.

OFFICE

Plot No. 465, Ground Floor, F.I.E., Patparganj Industrial Area, Delhi, India- 110092.

PHONE

+91-99682-17333

*Certain statements on this site are forward-looking within the meaning of federal securities laws. Please see our full disclaimer here.

A Cambridge, MA, based global healthcare platform synergizing biotech, medical devices, and AI.

Vyome Holdings, Inc.
Nasdaq: HIND

PRINCIPAL OFFICE

Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138

PHONE

+1 973-832-8147

SUBSIDIARIES

⁠Vyome Therapeutics, Inc.

OFFICE

Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138

Vyome Therapeutics Limited, Subsidiary of Vyome Therapeutics, Inc.

OFFICE

Plot No. 465, Ground Floor, F.I.E., Patparganj Industrial Area, Delhi, India- 110092.

PHONE

+91-99682-17333

*Certain statements on this site are forward-looking within the meaning of federal securities laws. Please see our full disclaimer here.

Vyome Holdings, Inc.
Nasdaq: HIND

PRINCIPAL OFFICE

Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138

PHONE

+1 973-832-8147

SUBSIDIARIES

⁠Vyome Therapeutics, Inc.

OFFICE

Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138

Vyome Therapeutics Limited, Subsidiary of Vyome Therapeutics, Inc.

OFFICE

Plot No. 465, Ground Floor, F.I.E., Patparganj Industrial Area, Delhi, India- 110092.

PHONE

+91-99682-17333

*Certain statements on this site are forward-looking within the meaning of federal securities laws. Please see our full disclaimer here.